

CITATION REPORT

List of articles citing

Rituximab: mechanism of action

DOI: 10.1053/j.seminhematol.2010.01.011
Seminars in Hematology, 2010, 47, 115-23.

Source: <https://exaly.com/paper-pdf/49646695/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
576	Immunotherapy of systemic sclerosis. <i>Immunotherapy</i> , 2010 , 2, 863-78	3.8	35
575	Rituximab as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma: profile report. 2011 , 25, 329-31		
574	Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms. 2011 , 4, 619-25		52
573	B cell depletion in autoimmune diabetes: insights from murine models. 2011 , 15, 703-14		2
572	The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF- κ B/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis. 2011 , 38, 1683-94		20
571	New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. 2011 , 25, 13-25		65
570	Novel antibodies against follicular non-Hodgkin's lymphoma. 2011 , 24, 231-56		18
569	Active and passive immunotherapy for lymphoma: proving principles and improving results. 2011 , 29, 1864-75		33
568	Rituximab: as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma. 2011 , 71, 885-95		4
567	Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. 2011 , 378, 1858-67		251
566	The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. 2011 , 25, 1502-9		138
565	Antibodies in oncology. 2011 , 28, 518-29		54
564	Cancer immunotherapy comes of age. 2011 , 29, 4828-36		336
563	Emerging drugs for the treatment of transplant rejection. 2011 , 16, 683-95		3
562	Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery?. 2011 , 6, 185-193		20
561	Molecular target therapy in hematological malignancy: front-runners and prototypes of small molecule and antibody therapy. 2011 , 41, 157-64		5
560	Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy. 2011 , 71, 5134-43		78

559	Immunogenicity and other problems associated with the use of biopharmaceuticals. 2011 , 2, 113-28	66
558	Novel antibody-based proteins for cancer immunotherapy. <i>Cancers</i> , 2011 , 3, 3370-93	6.6 3
557	Lonely killers: effector cell- and complement-independent non-proapoptotic cytotoxic antibodies inducing membrane lesions. 2011 , 3, 528-34	5
556	Immunogenicity of an inactivated monovalent 2009 influenza A (H1N1) vaccine in patients who have cancer. 2012 , 17, 125-34	15
555	Rituximab-Associated Occurrence of Disseminated Miliary Tuberculosis. 2012 , 20, 82-84	2
554	Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells. 2012 , 23, 376-86	82
553	Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. 2012 , 27, 1910-5	96
552	Recent advances in the application of antibodies as therapeutics. 2012 , 4, 73-86	7
551	Follicular lymphoma and the immune system: from pathogenesis to antibody therapy. 2012 , 119, 3659-67	28
550	Glyceroluria and neonatal hemochromatosis. 2012 , 55, e126-8	4
549	Combination of cyclophosphamide, rituximab, and intratumoral CpG oligodeoxynucleotide successfully eradicates established B cell lymphoma. 2012 , 35, 534-43	10
548	Giant cell hepatitis and immune thrombocytopenic purpura: reversal of liver failure with rituximab therapy. 2012 , 55, e128-30	6
547	Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. 2012 , 18, 6580-7	415
546	CD22 and autoimmune disease. 2012 , 31, 363-78	36
545	Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. 2012 , 120, 3986-96	223
544	Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. 2012 , 122, 3260-70	160
543	A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders. 2012 , 18, 5752-60	50
542	Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL). 2012 , 26, 991-1000	34

541	Managing post-transplant lymphoproliferative disorders in solid-organ transplant recipients: a review of immunosuppressant regimens. 2012 , 72, 1631-43	25
540	Hematological Cancers. 2012 , 279-325	
539	HLA desensitization in pediatric heart transplant candidates: efficacy of rituximab and IVIg. 2012 , 31, 1041-2	18
538	A sensitive approach. 2012 , 31, 1042-3	
537	Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy. 2012 , 7, e37671	63
536	4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia. 2012 , 42, 737-48	22
535	Fc-fusion proteins: new developments and future perspectives. 2012 , 4, 1015-28	279
534	Antibody therapy of cancer. 2012 , 12, 278-87	1519
533	Validation of a Gyrolab assay for quantification of rituximab in human serum. 2012 , 65, 107-14	19
532	The novel tribody [(CD20) ² xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells. 2013 , 27, 190-201	42
531	IL2/IL21 region polymorphism influences response to rituximab in systemic lupus erythematosus patients. 2013 , 40, 4851-6	11
530	Available evidence and outcome of off-label use of rituximab in clinical practice. 2013 , 69, 1689-99	8
529	Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. 2013 , 27, 495-507	134
528	Activation of complement by monoclonal antibodies that target cell-associated β microglobulin: implications for cancer immunotherapy. 2013 , 56, 549-60	13
527	Management of Recalcitrant Autoimmune Hepatitis. 2013 , 12, 66-77	4
526	The prognostic impact of absolute lymphocyte and monocyte counts at diagnosis of diffuse large B-cell lymphoma in the rituximab era. <i>Acta Haematologica</i> , 2013 , 130, 242-6	2-7 25
525	Stem Cells and Cancer Stem Cells, Volume 10. 2013 ,	
524	B-cell depletion therapy and pregnancy outcome in severe, refractory systemic autoimmune diseases. 2013 , 43, 55-9	41

523	Imaging and measuring the biophysical properties of Fc gamma receptors on single macrophages using atomic force microscopy. 2013 , 438, 709-14	15
522	Reprint of: B cell elimination in systemic lupus erythematosus. <i>Clin. Immunol.</i> 146(2) 90-103. 2013 , 148, 344-58	2
521	NK cells from an AML patient have recovered in remission and reached comparable cytolytic activity to that of a healthy monozygotic twin mediated by the single-chain triplebody SPM-2. 2013 , 11, 289	12
520	Detection of the FCGR3a polymorphism using a real-time polymerase chain reaction assay. 2013 , 206, 130-4	10
519	Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials. 2013 , 13, 803-11	43
518	Comparison of various criteria in interpreting end of therapy F-18 labeled fluorodeoxyglucose positron emission tomography/computed tomography in patients with aggressive non-Hodgkin lymphoma. 2013 , 54, 714-9	12
517	Long-term outcome of intravenous therapy with rituximab in patients with primary cutaneous B-cell lymphomas. 2013 , 169, 1126-32	15
516	Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. 2013 , 5, 826-37	83
515	GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present. 2013 , 54, 2500-5	48
514	Transient removal of CD46 is safe and increases B-cell depletion by rituximab in CD46 transgenic mice and macaques. 2013 , 21, 291-9	17
513	RANKL expression, function, and therapeutic targeting in multiple myeloma and chronic lymphocytic leukemia. 2013 , 73, 683-94	46
512	B-cell depletion in immune thrombocytopenia. <i>Seminars in Hematology</i> , 2013 , 50 Suppl 1, S75-82	4 13
511	The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP. 2013 , 13, 15-8	28
510	Cells and cell lysates: a direct approach for engineering antibodies against membrane proteins using yeast surface display. 2013 , 60, 27-37	40
509	Nanoscale mapping and organization analysis of target proteins on cancer cells from B-cell lymphoma patients. 2013 , 319, 2812-21	25
508	Rituximab-induced acute severe thrombocytopenia: a case series in patients with mantle cell lymphoma. 2013 , 13, 602-5	9
507	Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. 2013 , 381, 1203-10	962
506	Ectopic germinal centers, BAFF and anti-B-cell therapy in myasthenia gravis. 2013 , 12, 885-93	68

505	B cell elimination in systemic lupus erythematosus. 2013 , 146, 90-103		33
504	Antibody-based therapy in colorectal cancer. <i>Immunotherapy</i> , 2013 , 5, 533-45	3.8	21
503	Generation of Antigen-Specific T Lymphocytes from Induced Pluripotent Stem Cells for Adoptive Immunotherapy. 2013 , 105-121		
502	Management of antibody-mediated rejection in transplantation. 2013 , 93, 1451-66		12
501	At diagnosis, diffuse large B-cell lymphoma patients show impaired rituximab-mediated NK-cell cytotoxicity. 2013 , 43, 1383-8		15
500	Lymphoproliferative disorders in immunocompromised individuals and therapeutic antibodies for treatment. <i>Immunotherapy</i> , 2013 , 5, 415-25	3.8	1
499	Generation and preclinical characterization of a Fc-optimized GTR-Ig fusion protein for induction of NK cell reactivity against leukemia. 2013 , 21, 877-86		13
498	CD20 mAb-Mediated Complement Dependent Cytotoxicity of Tumor Cells is Enhanced by Blocking the Action of Factor I. 2013 , 2, 598-616		12
497	Preliminary analysis of mortality associated with rituximab use in autoimmune diseases. 2013 , 46, 487-96		15
496	The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy. 2013 , 88, 1062-7		44
495	Clinical outcome of elderly patients with Epstein-Barr virus positive diffuse large B-cell lymphoma treated with a combination of rituximab and CHOP chemotherapy. 2013 , 88, 774-9		29
494	Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. 2013 , 122, 3482-91		172
493	Antitumor Immunity and Dietary Compounds. 2014 , 2, 1-22		1
492	B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study. 2014 , 1,		67
491	Altered active zones, vesicle pools, nerve terminal conductivity, and morphology during experimental MuSK myasthenia gravis. 2014 , 9, e110571		17
490	Influence of NK cell count on the survival of patients with diffuse large B-cell lymphoma treated with R-CHOP. 2014 , 49, 162-9		11
489	Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations. 2014 , 63, 650-4		32
488	Transient wheal attack corresponding to the tumor lesions of primary cutaneous diffuse large B cell lymphoma, leg type after successive rituximab treatment. 2014 , 6, 218-21		2

487	In pursuit of a moving target: nanotherapeutics for the treatment of non-Hodgkin B-cell lymphoma. 2014 , 11, 1923-37		25
486	A higher frequency of CD4+CXCR5+ T follicular helper cells in adult patients with minimal change disease. 2014 , 2014, 836157		5
485	Genetic Susceptibility to ANCA-Associated Vasculitis: State of the Art. <i>Frontiers in Immunology</i> , 2014 , 5, 577	8.4	16
484	Molecular and Cellular Pathways of Immunoglobulin G Activity In Vivo. 2014 , 2014, 1-13		3
483	Dissecting the antibody constant region protective immune parameters in HIV infection. 2014 , 9, 397-414		8
482	Rituximab-related urticarial reaction overlying primary cutaneous follicle centre lymphoma: histological appearance and pathophysiological hypotheses. 2014 , 28, 976-8		6
481	Vemurafenib significantly decreases glomerular filtration rate. 2014 , 28, 978-9		16
480	Review of bortezomib treatment of antibody-mediated rejection in renal transplantation. 2014 , 21, 2401-18		34
479	Nanoscale distribution of CD20 on B-cell lymphoma tumour cells and its potential role in the clinical efficacy of rituximab. 2014 , 254, 19-30		16
478	Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma. 2014 , 20, 1029-41		32
477	Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3 β) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies. 2014 , 3, 31		1
476	Harnessing the Fc γ receptor for potent and selective cytotoxic therapy of chronic lymphocytic leukemia. 2014 , 74, 7510-7520		11
475	Current concepts in the diagnosis and management of cytokine release syndrome. 2014 , 124, 188-95		1520
474	Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013. 2014 , 55, 1609-17		35
473	The lower peripheral blood lymphocyte/monocyte ratio assessed during routine follow-up after standard first-line chemotherapy is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. 2014 , 38, 323-8		17
472	Is B-cell depletion still a good strategy for treating immune thrombocytopenia?. 2014 , 43, e79-85		11
471	Viral warfare! Front-line defence and arming the immune system against cancer using oncolytic vaccinia and other viruses. 2014 , 12, 210-20		5
470	Increased 8-hydroxy-2'-deoxyguanosine in plasma and decreased mRNA expression of human 8-oxoguanine DNA glycosylase 1, anti-oxidant enzymes, mitochondrial biogenesis-related proteins and glycolytic enzymes in leucocytes in patients with systemic lupus erythematosus. 2014 , 176, 66-77		43

469	Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease. 2014 , 16, 1453-1466	41
468	Drugs Targeting B-Cells in Autoimmune Diseases. 2014 ,	3
467	Rituximab for minimal change disease in adults: long-term follow-up. 2014 , 29, 851-6	45
466	Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients. 2014 , 74, 1057-64	36
465	Murine carcinoma expressing carcinoembryonic antigen-like protein is restricted by antibody against neem leaf glycoprotein. 2014 , 162, 132-9	4
464	Progress in measuring biophysical properties of membrane proteins with AFM single-molecule force spectroscopy. 2014 , 59, 2717-2725	12
463	Multifunctional nanocarriers for simultaneous encapsulation of hydrophobic and hydrophilic drugs in cancer treatment. 2014 , 9, 1499-515	31
462	Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety. 2014 , 41, 623-36	44
461	Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. 2014 , 32, 3242-8	94
460	Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies. 2014 , 86, 485-91	36
459	A hybrid protein-polymer nanoworm potentiates apoptosis better than a monoclonal antibody. 2014 , 8, 2064-76	43
458	Somatic alterations as the basis for resistance to targeted therapies. 2014 , 232, 244-54	27
457	Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR [®] therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. 2014 , 32, 1213-25	18
456	Peripheral blood lymphocyte/monocyte ratio at the time of first relapse predicts outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. 2014 , 14, 341	29
455	Obinutuzumab (Gazyva [®]), a Novel Glycoengineered Type II CD20 Antibody for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma. 2014 , 1695-1732	2
454	Ofatumumab (Arzerra [®]): a Next-Generation Human Therapeutic CD20 Antibody with Potent Complement-Dependent Cytotoxicity. 2014 , 1733-1774	
453	The natural history of intravascular lymphomatosis. 2014 , 3, 1010-24	55
452	Impact of rituximab trials on the treatment of ANCA-associated vasculitis. 2014 , 29, 1151-9	29

451	Anti-CD37 antibodies for chronic lymphocytic leukemia. 2014 , 14, 651-61		22
450	Human T-follicular helper and T-follicular regulatory cell maintenance is independent of germinal centers. 2014 , 124, 2666-74		81
449	Rituximab as an alternative for patients with severe systemic vasculitis refractory to conventional therapy: report of seven cases and literature review. 2015 , 55, 531-5		3
448	Rituximab use in young adults diagnosed with juvenile idiopathic arthritis unresponsive to conventional treatment: report of 6 cases. 2015 , 55, 536-541		0
447	Imaging and mapping individual target proteins on clinical lymphoma cells by AFM. 2015 ,		1
446	Computational Methods in the Optimization of Biologic Modalities. 2015 , 35-60		
445	Immunogenicity considerations. 2015 , 23-66		
444	Antibody-drug conjugates as novel anti-cancer chemotherapeutics. 2015 , 35,		237
443	Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma. 2015 , 125, 82-9		37
442	A new rescue regimen with plasma exchange and rituximab in high-risk membranous glomerulonephritis. 2015 , 45, 1260-9		19
441	Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era. <i>Medicine (United States)</i> , 2015 , 94, e993	1.8	40
440	Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia. 2015 , 9, 75-86		2
439	Chronic Renal Transplant Rejection and Possible Anti-Proliferative Drug Targets. 2015 , 7, e376		13
438	Challenges in Antibody Development against Tn and Sialyl-Tn Antigens. 2015 , 5, 1783-809		47
437	Importance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other FcγReceptors. 2015 , 10, e0140120		20
436	Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives. 2015 , 11, 1749-58		3
435	Atypical Endobronchial Carcinoid with Postobstructive Pneumonia Obscuring the Diagnosis of Granulomatosis with Polyangiitis. 2015 , 2015, 513602		
434	The emerging role of rituximab in autoimmune blistering diseases. 2015 , 16, 167-77		9

433	Building better monoclonal antibody-based therapeutics. 2015 , 15, 361-70	411
432	Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients. 2015 , 4, e990773	20
431	Nanoscale monitoring of drug actions on cell membrane using atomic force microscopy. 2015 , 36, 769-82	34
430	Cancer Immunoediting: Immunosurveillance, Immune Equilibrium, and Immune Escape. 2015 , 195-208	2
429	Afucosylated antibodies increase activation of FcγRIIIa-dependent signaling components to intensify processes promoting ADCC. 2015 , 3, 173-83	45
428	Ofatumumab for treating chronic lymphocytic leukemia: a safety profile. 2015 , 14, 1945-59	11
427	Kinetics of B, T, NK lymphocytes and isoagglutinin titers in ABO incompatible living donor liver transplantation using rituximab and basiliximab. 2015 , 32, 29-34	18
426	Tumor-associated hyaluronan limits efficacy of monoclonal antibody therapy. 2015 , 14, 523-32	89
425	Monoclonal antibodies: pharmacokinetics as a basis for new dosage regimens?. 2015 , 21, 370-6	5
424	Novel investigational therapies for atopic dermatitis. 2015 , 24, 61-68	16
423	Prognostic role of peripheral blood lymphocyte/monocyte ratio at diagnosis in diffuse large B-cell lymphoma: a meta-analysis. 2015 , 56, 2563-8	27
422	Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. 2015 , 100, 77-86	115
421	An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia. 2015 , 136, 1073-84	27
420	Lenalidomide differently modulates CD20 antigen surface expression on chronic lymphocytic leukemia B-cells. 2015 , 56, 2458-9	2
419	Understanding of molecular mechanisms in natural killer cell therapy. 2015 , 47, e141	43
418	The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma. 2015 , 10, 791-808	7
417	Emerging immunological drugs for chronic lymphocytic leukemia. 2015 , 20, 423-47	9
416	Mechanisms of action of therapeutic antibodies for cancer. 2015 , 67, 28-45	98

415	Quantitative analysis of drug-induced complement-mediated cytotoxic effect on single tumor cells using atomic force microscopy and fluorescence microscopy. 2015 , 14, 84-94	21
414	Fungal Infections in the Era of Biologic Therapies. 2015 , 2, 76-83	6
413	Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature. 2015 , 39, 739-48	11
412	Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab. 2015 , 3, 567-74	28
411	PKD1 is critical for Epstein-Barr virus LMP1-induced protection of malignant B cells from cell death induced by rituximab. 2015 , 56, 194-201	3
410	Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma. 2015 , 17, 41	15
409	Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. 2015 , 169, 544-51	16
408	Rituximab use in young adults diagnosed with juvenile idiopathic arthritis unresponsive to conventional treatment: report of 6 cases. 2015 , 55, 536-41	7
407	Biobetters. 2015 ,	1
406	Anti-apoptotic role and clinical relevance of neurotrophins in diffuse large B-cell lymphomas. 2015 , 113, 934-44	20
405	Antibody-based immunotherapy of solid cancers: progress and possibilities. <i>Immunotherapy</i> , 2015 , 7, 923-39	3.8 17
404	Rituximab as an alternative for patients with severe systemic vasculitis refractory to conventional therapy: report of seven cases and literature review. 2015 , 55, 531-535	1
403	Antibody-Like Molecules Designed for Superior Targeting and Pharmacokinetics. 2015 , 203-220	
402	Cell mediators of autoimmune hepatitis and their therapeutic implications. 2015 , 60, 1528-42	26
401	IgG1 anti-epidermal growth factor receptor antibodies induce CD8-dependent antitumor activity. 2015 , 136, 821-30	16
400	Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential. 2015 , 56, 219-25	35
399	Pharmacologic Considerations in Oncology Critical Care. 2016 ,	1
398	. 2016 ,	4

397	Genetic and Epigenetic Modulation of CD20 Expression in B-Cell Malignancies: Molecular Mechanisms and Significance to Rituximab Resistance. 2016 , 56, 89-99	26
396	Evaluation of Anti-inflammatory Effects of Steroids and Arthritis-Related Biotherapies in an Coculture Model with Immune Cells and Synoviocytes. <i>Frontiers in Immunology</i> , 2016 , 7, 509	8.4 5
395	A Case of Organizing Pneumonia (OP) Associated with Pembrolizumab. 2016 , 10, 9-12	18
394	Rituximab-induced Cytokine Storm in the Absence of Overt Lymphoproliferative Disease. 2016 , 38, e29-31	11
393	Treatment of catastrophic antiphospholipid syndrome. 2016 , 28, 218-27	51
392	Rituximab induces phenotypical and functional changes of NK cells in a non-malignant experimental setting. 2016 , 18, 206	15
391	Mechanism of Action for Therapeutic Antibodies. 2016 , 85-111	2
390	Development of Biosimilar Rituximab and Clinical Experience. 2016 , 269-281	
389	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. 2016 , 4, 90	14
388	Rituximab in autoimmune connective tissue disease-associated interstitial lung disease. 2016 , 55, 1318-24	63
387	Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer. 2016 , 13, 999-1013	6
386	Comparability of Antibody-Mediated Cell Killing Activity Between a Proposed Biosimilar RTX83 and the Originator Rituximab. 2016 , 30, 225-31	14
385	A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition. 2016 , 16, 35	13
384	Management of Small Vessel Vasculitides. 2016 , 18, 36	7
383	Current and future immunotherapy targets in autoimmune neurology. 2016 , 133, 511-36	3
382	FCG (FLIPI, Charlson comorbidity index, and histological grade) score is superior to FLIPI in advanced follicular lymphoma. 2016 , 104, 692-699	6
381	The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fc γ receptor. 2016 , 8, 1512-1524	105
380	Low natural killer (NK) cell counts in peripheral blood adversely affect clinical outcome of patients with follicular lymphoma. 2016 , 6, e457	12

379	Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes. 2016 , 16, 91		3
378	The safety profile of monoclonal antibodies for chronic lymphocytic leukemia. 2017 , 16, 185-201		3
377	Rapid recognition and functional analysis of membrane proteins on human cancer cells using atomic force microscopy. 2016 , 436, 41-9		7
376	Outcome Comparison of Allogeneic versus Autologous Stem Cell Transplantation in Transformed Low-Grade Lymphoid Malignancies: A Systematic Review and Pooled Analysis of Comparative Studies. <i>Acta Haematologica</i> , 2016 , 136, 244-255	2.7	8
375	Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment. 2016 , 37, 993-1008		97
374	Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis. 2016 , 3, ofw205		60
373	USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphoma. 2016 , 8, 851-62		37
372	Transient Impact of Rituximab in H1N1 Vaccination-associated Narcolepsy With Severe Psychiatric Symptoms. 2016 , 21, 85-6		14
371	Characterizing the effect of multiple Fc glycan attributes on the effector functions and FcγRIIIa receptor binding activity of an IgG1 antibody. 2016 , 32, 1181-1192		11
370	Mouse Models of Tumor Immunotherapy. 2016 , 130, 1-24		25
369	Ofatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association data. 2016 , 7, 222-30		2
368	Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. <i>Journal of Neurology</i> , 2016 , 263, 1727-35	5.5	35
367	Targeting B-cell non Hodgkin lymphoma: New and old tricks. 2016 , 42, 93-104		29
366	Biologics in pregnancy [for the obstetrician]. 2016 , 18, 25-32		6
365	Overcoming a species-specificity barrier in development of an inhibitory antibody targeting a modulator of tumor stroma. 2016 , 29, 135-47		7
364	Nanoscale Quantifying the Effects of Targeted Drug on Chemotherapy in Lymphoma Treatment Using Atomic Force Microscopy. 2016 , 63, 2187-99		18
363	CD20-Targeting Immunotherapy Promotes Cellular Senescence in B-Cell Lymphoma. 2016 , 15, 1074-81		16
362	Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?. 2016 , 16, 655-74		15

361	Role of Rituximab and Rituximab Biosimilars in Diffuse Large B-Cell Lymphoma. 2016 , 16, 175-81	23
360	Activity of 8F4, a T-cell receptor-like anti-PR1/HLA-A2 antibody, against primary human AML in vivo. 2016 , 30, 1475-84	24
359	War and peace: Factor VIII and the adaptive immune response. 2016 , 301, 2-7	9
358	Clinical relevance of circulating antibodies and B lymphocyte markers in allograft rejection. 2016 , 49, 385-93	2
357	The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy. 2016 , 12, 41-55	18
356	Applications of Atomic Force Microscopy in Exploring Drug Actions in Lymphoma-Targeted Therapy at the Nanoscale. 2016 , 6, 22-32	4
355	Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy. 2016 , 22, 86-95	60
354	Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions. 2016 , 99, 87-96	48
353	CD47 limits antibody dependent phagocytosis against non-malignant B cells. 2017 , 85, 57-65	5
352	Standard of care in immunotherapy trials: Challenges and considerations. 2017 , 13, 2164-2178	4
351	Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity. 2017 , 129, 2246-2256	15
350	Changes in Cancer Treatment: Mabs, Mibs, Mids, Nabs, and Nibs. 2017 , 52, 65-81	11
349	Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. 2017 , 22, 549-553	3
348	Prognostic impact of absolute lymphocyte count/absolute monocyte count ratio and prognostic score in patients with nasal-type, extranodal natural killer/T-cell lymphoma. 2017 , 39, 1010428317705503	12
347	B Cell Biology. 2017 , 97-119	1
346	Post-transplant lymphoproliferative disorders. 2017 , 369-375	
345	Rituximab treatment in pemphigus vulgaris: effect on circulating Tregs. 2017 , 309, 551-556	9
344	Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis. 2017 , 31, 369-377	33

343	Humanization of chimeric anti-CD20 antibody by logical and bioinformatics approach with retention of biological activity. <i>Immunotherapy</i> , 2017 , 9, 567-577	3.8	3
342	Pediatric Myasthenia Gravis: A Review. 2017 , 15, 062-069		
341	Conformational effects of N-glycan core fucosylation of immunoglobulin G Fc region on its interaction with Fcγ receptor IIIa. 2017 , 7, 13780		44
340	Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis. 2017 , 10, 470-474		28
339	Humanized mouse model supports development, function, and tissue residency of human natural killer cells. 2017 , 114, E9626-E9634		94
338	Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia. 2017 , 10, 1069-1076		6
337	Diagnosis and management of Neuromyelitis Optica Spectrum Disorder (NMOSD) in Iran: A consensus guideline and recommendations. 2017 , 18, 144-151		22
336	Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development. 2017 , 34, 2210-2231		39
335	Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. 2017 , 34, 2232-2273		227
334	NK Cells and T _H Cells for Relapse Protection After Allogeneic Hematopoietic Cell Transplantation (HCT). 2017 , 3, 301-311		10
333	Rationale for Adjunctive Therapies for Pediatric Sepsis Induced Multiple Organ Failure. 2017 , 64, 1071-1088		11
332	Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors. 2017 , 54, 31-39		13
331	Safety and Efficacy of Immunoabsorption as an Add-On to Medical Treatment in Patients with Severe Idiopathic Pulmonary Arterial Hypertension. 2017 , 94, 263-271		1
330	Lupus nephritis and B-cell targeting therapy. 2017 , 13, 951-962		17
329	Prognostic value of lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio in follicular lymphoma: a retrospective cohort study. 2017 , 7, e017904		17
328	Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments. 2017 , 12, 719-739		51
327	Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab. 2017 , 19, 44		6
326	Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived Xenografts. 2017 , 19, 628-636		35

325	Direct targeting of cancer cells with antibodies: What can we learn from the successes and failure of unconjugated antibodies for lymphoid neoplasias?. 2017 , 85, 6-19		8
324	Peripheral blood lymphocyte/monocyte ratio following completion of first-line therapy predicts early relapse in patients with diffuse large B cell lymphoma. 2017 , 96, 237-243		3
323	Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy. 2017 , 23, 954-961		8
322	Natural killer cells in malignant hematology: A primer for the non-immunologist. 2017 , 31, 1-10		27
321	An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia. 2017 , 31, 459-469		33
320	. 2017 ,		2
319	An Introduction to Terminology and Methodology of Chemical Synergy-Perspectives from Across Disciplines. 2017 , 8, 158		102
318	Translational Aspects of Sphingolipid Metabolism in Renal Disorders. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	13
317	Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies. 2017 , 5,		24
316	Relapsing granulomatosis with polyangiitis with severe lung and upper respiratory tract involvement successfully treated with rituximab. 2017 , 55, 208-212		1
315	Monoclonal Antibodies. 2017 , 71-95		3
314	Strategies for Selecting Membrane Protein-Specific Antibodies using Phage Display with Cell-Based Panning. 2017 , 6,		17
313	Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields. <i>Frontiers in Immunology</i> , 2017 , 8, 1112	8.4	11
312	Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?. <i>Frontiers in Immunology</i> , 2017 , 8, 1245	8.4	80
311	New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness. <i>Frontiers in Immunology</i> , 2017 , 8, 1804	8.4	38
310	A case of a focal oedematous reaction induced by rituximab overlying lupus erythematosus tumidus. 2017 , 27, 542-543		2
309	Immunosuppression in pregnant women with renal disease: review of the latest evidence in the biologics era. 2018 , 31, 361-383		14
308	Subcutaneous rituximab with recombinant human hyaluronidase in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia. 2018 , 14, 1691-1699		3

307	Early Reconstitution of NK and T Cells and Its Implication for the Design of Post-Transplant Immunotherapy. 2018 , 24, 1152-1162	27
306	A presentation of ulcerative colitis after rituximab therapy in a patient with multiple sclerosis and literature review. 2018 , 22, 22-26	12
305	Rituximab-related Severe Toxicity. 2018 , 579-596	1
304	Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation. 2018 , 18, 13	2
303	A comparison of desensitization methods: Rituximab with/without plasmapheresis in ABO-incompatible living donor liver transplantation. 2018 , 17, 119-125	14
302	Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study. 2018 , 7, 1043-1055	20
301	Advances in HCV and Cryoglobulinemic Vasculitis in the Era of DAAs: Are We at the End of the Road?. 2018 , 8, 81-94	14
300	Pathways Linked to Cancer Chemoresistance and Their Targeting by Nutraceuticals. 2018 , 1-30	1
299	Immunoengineering with biomaterials for enhanced cancer immunotherapy. 2018 , 10, e1506	22
298	Elevated absolute NK cell counts in peripheral blood predict good prognosis in chronic lymphocytic leukemia. 2018 , 144, 449-457	19
297	Immunology of idiopathic nephrotic syndrome. 2018 , 33, 573-584	55
296	Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. 2018 , 181, 413-417	19
295	Anti-CD20 Blocker Rituximab in Kidney Transplantation. 2018 , 102, 44-58	19
294	Treatment Options for Resistant Kawasaki Disease. 2018 , 20, 59-80	14
293	CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy. 2017 , 7, e1380142	13
292	Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study. 2018 , 10, 143-158	35
291	The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars. 2018 , 23, 288-296	3
290	Effects of complement and serum IgG on rituximab-dependent natural killer cell-mediated cytotoxicity against Raji cells. 2019 , 17, 339-347	4

289	Rituximab therapy for patients with Langerhans cell histiocytosis-associated neurologic dysfunction. 2018 , 35, 427-433		3
288	Optimization of Large-Scale Expansion and Cryopreservation of Human Natural Killer Cells for Anti-Tumor Therapy. 2018 , 18, e31		19
287	Neutrophils: Novel key players in Rheumatoid Arthritis. Current and future therapeutic targets. 2018 , 17, 1138-1149		47
286	Targeted Treatments for Hematological Cancers. 2018 , 259-312		
285	An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma. 2018 , 18, 508-518.e14		10
284	Drugs Used in Rheumatic Disease. 2018 , 15, 39-76		2
283	Hypersensitivity Reactions: Priming Practice Change to Reduce Incidence in First-Dose Rituximab Treatment. 2018 , 22, 407-414		2
282	Molecular Targeted Therapy of Pediatric Neoplasms. 2018 , 67-86		
281	Cancer nanomedicine: mechanisms, obstacles and strategies. 2018 , 13, 1639-1656		27
280	Development of Antibody Therapeutics against Flaviviruses. <i>International Journal of Molecular Sciences</i> , 2017 , 19,	6.3	37
279	Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy. <i>Frontiers in Oncology</i> , 2018 , 8, 163	5.3	118
278	slan Monocytes and Macrophages Mediate CD20-Dependent B-cell Lymphoma Elimination via ADCC and ADCP. 2018 , 78, 3544-3559		17
277	Determination of optimum vitamin D3 levels for NK cell-mediated rituximab- and obinutuzumab-dependent cellular cytotoxicity. 2018 , 67, 1709-1718		3
276	EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs. <i>Cancers</i> , 2018 , 10,	6.6	28
275	Human Papillomavirus- and EpsteinBarr Virus-Caused Tumor Diagnosis and Therapy. 2018 , 133-160		
274	Immunomodulatory Functions of the Gastrointestinal Tract. 2018 , 685-771		1
273	Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease. 2019 , 58, 567-579		35
272	Dual effects of an anti-CD147 antibody for Esophageal cancer therapy. 2019 , 20, 1443-1452		5

271	Review of Graft-Versus-Host Disease. 2019 , 37, 569-582		41
270	ABO-Incompatible Adult Living Donor Liver Transplantation in the Era of Rituximab: A Systematic Review and Meta-Analysis. 2019 , 2019, 8589402		11
269	Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: a secondary analysis of a randomized clinical trial. 2019 , 145, 2149-2156		2
268	Hepatitis B Virus Reactivation: Risk Factors and Current Management Strategies. 2019 , 39, 1190-1203		20
267	Implication of Rituximab Infusion Reactions on Clinical Outcomes in Patients With Diffuse Large B-cell Lymphoma: A Single Institution Experience. 2019 , 19, 806-811		2
266	Ocrelizumab: A New Generation of anti-CD20 mAb for Treatment of Multiple Sclerosis. 2019 , 169-199		
265	Scientific rationale underpinning the development of biosimilar rituximab in hematological cancers and inflammatory diseases. 2019 , 15, 4223-4234		4
264	Combination Radioimmunotherapy Strategies for Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	17
263	Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	16
262	Principles of Cancer Treatment and Anticancer Drug Development. 2019 ,		3
261	Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases. 2019 , 17, 61		25
260	NK Cells in the Treatment of Hematological Malignancies. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	24
259	Clinical and histopathological findings of patients with orbital granulomatosis with polyangiitis cases refractory to rituximab. 2019 , 54, 682-687		3
258	Rekombinante Antikörper. 2019 ,		0
257	Human neutrophils express low levels of FcβRIIIA, which plays a role in PMN activation. 2019 , 133, 1395-1405		22
256	Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?. 2019 , 104, 1124-1135		27
255	Aging, Cancer and Immunity. 2019 , 10, 3021-3027		31
254	Desensitization in heart transplant recipients: Who, when, and how. 2019 , 33, e13639		2

253	An Fc-Optimized CD133 Antibody for Induction of Natural Killer Cell Reactivity against Colorectal Cancer. <i>Cancers</i> , 2019 , 11,	6.6	5
252	Immunology and Immunotherapy in Critical Care: An Overview. 2019 , 30, 113-125		3
251	Effects of Rituximab on Atherosclerotic Biomarkers in Kidney Transplant Recipients. 2019 , 51, 1118-1120		1
250	Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy. 2019 , 25, 4634-4643		30
249	Treatment of hematological malignancies with T cell redirected bispecific antibodies: current status and future needs. 2019 , 19, 707-720		7
248	Immunosuppressive therapy with rituximab in common variable immunodeficiency. 2019 , 17, 9		23
247	Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents. 2019 , 9, 944-961		20
246	Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases. 2019 , 85, 1790-1797		6
245	Laquinimod, a prototypic quinoline-3-carboxamide and aryl hydrocarbon receptor agonist, utilizes a CD155-mediated natural killer/dendritic cell interaction to suppress CNS autoimmunity. 2019 , 16, 49		14
244	Binary Targeting of siRNA to Hematologic Cancer Cells using Layer-by-Layer Nanoparticles. 2019 , 29, 1900018		48
243	Canine CD117-Specific Antibodies with Diverse Binding Properties Isolated from a Phage Display Library Using Cell-Based Biopanning. 2019 , 8,		2
242	Physicochemical and Biological Characterization of RTX83, a New Rituximab Biosimilar. 2019 , 33, 307-319		12
241	Low absolute NK cell counts in peripheral blood are associated with inferior survival in patients with mantle cell lymphoma. 2019 , 24, 439-447		6
240	Benralizumab for -Negative Hypereosinophilic Syndrome. 2019 , 380, 1336-1346		81
239	Rituximab in kidney disease and transplant. 2019 , 2, 76-82		8
238	Biosimilars: what the oncologist should know. 2019 , 15, 1147-1165		13
237	Drug screening approach combines epigenetic sensitization with immunochemotherapy in cancer. 2019 , 11, 192		1
236	Emerging treatment options for patients with p53-pathway-deficient CLL. 2019 , 10, 2040620719891356		12

235	Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody. <i>Cancers</i> , 2019 , 11,	6.6	6
234	Rituximab as a novel treatment for heart failure: evidence from a case series. 2019 , 3, 1-2		1
233	Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules. 2019 , 39, 265-301		85
232	Bendamustine alone or with rituximab modifies expression of apoptosis-regulating genes and proteins of CLL cells, depending on IGVH mutational status. 2019 , 60, 1409-1419		
231	Sex differences in vaccine-induced humoral immunity. 2019 , 41, 239-249		125
230	Co-engaging CD47 and CD19 with a bispecific antibody abrogates B-cell receptor/CD19 association leading to impaired B-cell proliferation. 2019 , 11, 322-334		16
229	Targets of monoclonal antibodies for immunological diseases. 2019 , 42, 293-304		3
228	Effector and regulatory B cells in immune-mediated kidney disease. 2019 , 15, 11-26		48
227	Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy. 2019 , 24, 1241-1247		10
226	Mature IgD B cells maintain tolerance by promoting regulatory T cell homeostasis. 2019 , 10, 190		16
225	Midostaurin potentiates rituximab antitumor activity in Burkitt's lymphoma by inducing apoptosis. 2018 , 10, 8		5
224	Infusion-related reactions to rituximab: frequency, mechanisms and predictors. 2019 , 15, 383-389		25
223	Human Monoclonal Antibodies. 2019 ,		
222	Humanization and Simultaneous Optimization of Monoclonal Antibody. 2019 , 1904, 213-230		4
221	Demystifying biosimilars: development, regulation and clinical use. 2019 , 15, 777-790		13
220	Rituximab in systemic autoimmune rheumatic diseases: indications and practical use. 2019 , 74, 272-279		14
219	Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration. 2019 , 48, 17-23		4
218	The in-use stability of the rituximab biosimilar Rixathon [®] /Riximyo [®] upon preparation for intravenous infusion. 2019 , 25, 269-278		12

217	Proposed rituximab biosimilar BCD-020 versus reference rituximab for treatment of patients with indolent non-Hodgkin lymphomas: An international multicenter randomized trial. <i>Hematological Oncology</i> , 2020 , 38, 67-73	1.3	3
216	Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study. 2020 , 188, 661-673		7
215	Severe but reversible pulmonary hypertension in scleromyxedema and multiple myeloma: a case report. 2020 , 20, 8		4
214	Review of rituximab in primary CNS lymphoma. 2020 , 410, 116649		2
213	B cells targeting therapy in the management of systemic lupus erythematosus. 2020 , 43, 16-35		12
212	Multifaceted assessment of rituximab biosimilarity: The impact of glycan microheterogeneity on Fc function. 2020 , 146, 111-124		8
211	Regulation of antibody-mediated complement-dependent cytotoxicity by modulating the intrinsic affinity and binding valency of IgG for target antigen. 2020 , 12, 1690959		11
210	[Localized urticarial rituximab-induced reaction in primary cutaneous marginal zone B-cell lymphoma]. 2020 , 147, 50-52		
209	Risk of relapse in patients with neuromyelitis optica spectrum disorder: Recognition and preventive strategy. 2020 , 46, 102522		4
208	Protective role of anticancer drugs in neurodegenerative disorders: A drug repurposing approach. 2020 , 140, 104841		5
207	Analytical and functional similarity of biosimilar ABP 798 with rituximab reference product. 2020 , 68, 79-91		8
206	Innovative Therapeutic Approaches in Primary Cutaneous B Cell Lymphoma. <i>Frontiers in Oncology</i> , 2020 , 10, 1163	5.3	4
205	Specification of biotechnology products. 2020 , 561-585		
204	Low Absolute Lymphocyte Counts in the Peripheral Blood Predict Inferior Survival and Improve the International Prognostic Index in Testicular Diffuse Large B-Cell Lymphoma. <i>Cancers</i> , 2020 , 12,	6.6	4
203	Immunotoxin Screening System: A Rapid and Direct Approach to Obtain Functional Antibodies with Internalization Capacities. 2020 , 12,		3
202	Rituximab in people living with HIV affected by immune-mediated renal diseases: a case-series. 2020 , 31, 1426-1431		0
201	Rituximab-induced acute thrombocytopenia in patients with splenomegaly B Cell lymphoma: an underdiagnosed but severe complication. 2020 , 21, 1060-1066		1
200	Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis. 2020 , 39, 3341-3352		7

199	Polymorphisms Involved in Response to Biological Agents Used in Rheumatoid Arthritis. 2020 , 10,	2
198	Novel Therapies for Pemphigus Vulgaris. 2020 , 21, 765-782	2
197	Targeted IgMs agonize ocular targets with extended vitreal exposure. 2020 , 12, 1818436	2
196	Immunosuppressive Agents and Infectious Risk in Transplantation: Managing the "Net State of Immunosuppression". 2021 , 73, e1302-e1317	20
195	The Role of Deubiquitinating Enzymes in Hematopoiesis and Hematological Malignancies. <i>Cancers</i> , 2020 , 12,	6.6 6
194	Transcriptional regulation of natural killer cell development and maturation. 2020 , 146, 1-28	9
193	Impact of mAb Aggregation on Its Biological Activity: Rituximab as a Case Study. 2020 , 109, 2684-2698	11
192	Cancer immunotherapy: dawn of the death of cancer?. 2020 , 1-18	1
191	The role of B cells in heart failure and implications for future immunomodulatory treatment strategies. 2020 , 7, 1387-1399	14
190	Outcomes of immunomodulatory and biologic therapy in people living with HIV. 2020 , 34, 1171-1179	3
189	Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: A meta-analysis. 2020 , 19, 102505	8
188	Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies. 2020 , 44, 100678	22
187	Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents. 2020 , 7, 303	22
186	Alternative management of Covid-19 infection. 2020 , 65, 72-75	4
185	FACS-Based Functional Protein Screening via Microfluidic Co-encapsulation of Yeast Secretor and Mammalian Reporter Cells. 2020 , 10, 10182	8
184	A Randomized, Double-Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid Arthritis. 2020 , 9, 1003-1014	6
183	Effects of rituximab therapy on B cell differentiation and depletion. 2020 , 39, 1415-1421	20
182	B-cell treatment in ANCA-associated vasculitis. 2020 , 59, iii68-iii73	0

181	Biomaterials for cancer immunotherapy. 2020 , 499-526		4
180	Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era. 2020 , 25, 793-802		6
179	Targeting an adenosine-mediated "don't eat me signal" augments anti-lymphoma immunity by anti-CD20 monoclonal antibody. 2020 , 34, 2708-2721		14
178	Rituximab in Ocular Adnexal Lymphoma and Orbital Inflammatory Disease. 2020 , 60, 63-75		
177	Ocular side effects of antirheumatic medications: a qualitative review. 2020 , 5, e000331		7
176	BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL. 2020 , 11, 2040620720912990		5
175	Mechanisms of Resistance to NK Cell Immunotherapy. <i>Cancers</i> , 2020 , 12,	6.6	17
174	Non-Hodgkin Lymphomas: Malignancies Arising from Mature B Cells. 2021 , 11,		1
173	CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. 2021 , 35, 75-89		51
172	Rituximab. 2021 , 330-338.e3		
171	Combination therapies utilizing neoepitope-targeted vaccines. 2021 , 70, 875-885		6
170	A general Fc engineering platform for the next generation of antibody therapeutics. 2021 , 11, 1901-1917		5
169	Serum sickness following rituximab therapy in a patient with pemphigus vulgaris: A case report. 2021 , 9, 751-754		0
168	A low lymphocyte-to-monocyte ratio is an independent predictor of poorer survival and higher risk of histological transformation in follicular lymphoma. 2021 , 62, 104-111		4
167	Antibody-drug conjugates for lung cancer in the era of personalized oncology. 2021 , 69, 268-278		8
166	Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?. <i>Frontiers in Immunology</i> , 2020 , 11, 595818	8.4	3
165	Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma. 2021 , 12, 2040620721989579		3
164	CCR7 as a therapeutic target in Cancer. 2021 , 1875, 188499		13

163	Overcoming the challenges associated with CD3+ T-cell redirection in cancer. 2021 , 124, 1037-1048	15
162	Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients. 2021 , 90, 107226	4
161	Recent advances in cellular therapy for malignant lymphoma. 2021 , 23, 662-671	2
160	Potential Effects of Immunosuppression on Oxidative Stress and Atherosclerosis in Kidney Transplant Recipients. 2021 , 2021, 6660846	2
159	Post-HDX Deglycosylation of Fc Gamma Receptor IIIa Glycoprotein Enables HDX Characterization of Its Binding Interface with IgG. 2021 , 32, 1638-1643	1
158	Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults. 2021 , 4, e2036321	9
157	Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model. 2021 , 9,	0
156	Targeting NK Cells to Enhance Melanoma Response to Immunotherapies. <i>Cancers</i> , 2021 , 13,	6.6 7
155	Belimumab: a step forward in the treatment of systemic lupus erythematosus. 2021 , 21, 563-573	4
154	On- and off-label use of rituximab in rheumatic diseases. 2021 , 3,	
153	Rose Extract Treatment on the CD4+ T lymphocytes.	
152	Rituximab in pemphigus vulgaris - Standard operating procedure. 1-4	
151	Antibody Therapy: From Diphtheria to Cancer, COVID-19, and Beyond. 2021 , 40, 36-49	4
150	Natural Killer cells and monoclonal antibodies: Two partners for successful antibody dependent cytotoxicity against tumor cells. 2021 , 160, 103261	7
149	Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis. 2021 , 49, 102787	6
148	pH-responsive zwitterionic carbon dots for detection of rituximab antibody. 2021 , 36, 1198-1208	4
147	Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3 9
146	Drug repurposing of dermatologic medications to treat coronavirus disease 2019: Science or fiction?. 2021 , 39, 430-445	1

145	The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions. 2021 , 12, 680043		9
144	Prognostic Significance of Systemic Immune-Inflammation Index in Patients With Diffuse Large B-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2021 , 11, 655259	5.3	3
143	COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review. 2021 , 41, 1509-1514		4
142	Management of Relapsed Hairy Cell Leukemia: A Systematic Review of Novel Agents and Targeted Therapies. 2021 , 21, 659-666		
141	Factor VIII-Fc Activates Natural Killer Cells Fc-Mediated Interactions With CD16. <i>Frontiers in Immunology</i> , 2021 , 12, 692157	8.4	0
140	Use of rituximab in paediatric nephrology. 2021 , 106, 1058-1065		2
139	Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma. 2021 , 27, 4726-4736		
138	Emerging drugs for the treatment of myasthenia gravis. 2021 , 26, 259-270		1
137	HBV Reactivation During the Treatment of Non-Hodgkin Lymphoma and Management Strategies. <i>Frontiers in Oncology</i> , 2021 , 11, 685706	5.3	4
136	Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data. 2021 , 46, 601-611		0
135	Hypersensitivity pneumonitis: Current concepts in pathogenesis, diagnosis, and treatment. 2021 ,		8
134	Biologics in autoimmune bullous diseases: Current scenario. 2021 , 87, 611-620		0
133	Ibrutinib plus rituximab for the treatment of adult patients with Waldenström's macroglobulinemia: a safety evaluation. 2021 , 20, 987-995		1
132	Comprehensive genetic and functional analysis of FcRs in rituximab therapy for autoimmunity reveals a key role for FcRIIIa on NK cells.		0
131	The Effect of Immunomodulatory Treatments on Anti-Dystrophin Immune Response After AAV Gene Therapy in Dystrophin Deficient mdx Mice. 2021 , 8, S325-S340		1
130	BL-01, an Fc-bearing, tetravalent CD20/CD5 bispecific antibody, redirects multiple immune cells to kill tumors in vitro and in vivo. 2021 ,		
129	Treatment of Connective Tissue Disease-Related Intractable Disease with Biological Therapeutics. 2021 , 13, 293-303		1
128	Immunological Response Against SARS-COV-2 After BNT162b2 Vaccine Administration Is Impaired in Allogeneic but Not in Autologous Stem Cell Transplant Recipients. <i>Frontiers in Oncology</i> , 2021 , 11, 737300	5.3	6

127	Development of a cell line-based assay to measure the antibody-dependent cellular cytotoxicity of a canine therapeutic antibody. 2021 , 240, 110315	1
126	Image-guided cancer immunotherapy. 2022 , 427-467	
125	Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma. 2021 , 10, 1928365	2
124	Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis. 2020 , 11, 595547	6
123	Immunosuppressive therapy in SLE. 2021 , 623-659	
122	Humanization and simultaneous optimization of monoclonal antibody. 2014 , 1060, 123-37	10
121	Pharmacological Effects and Mechanisms of Action of Agents Blocking B Cells. 2014 , 37-64	1
120	Systemic Lupus Erythematosus: Direct B-Cell Blocking. 2014 , 65-78	1
119	A Toolbox of Potential Immune-Related Therapies for Inflammatory Cardiomyopathy. 2021 , 14, 75-87	4
118	Disease modifying drugs for rheumatological diseases: a brief history of everything. 2020 , 120, 313-348	2
117	Dysfunctional Immune System Reconstitution After Rituximab Exposure In Utero. 2021 , 43, e601-e604	0
116	A curative combination therapy for lymphomas achieves high fractional cell killing through low cross-resistance and drug additivity but not synergy.	2
115	Toxicity Management: Development of a Novel and Immune-Mediated Adverse Events Algorithm?. 2017 , 21, 53-59	4
114	The p53 Mutation/Deletion Profile in a Small Cohort of the Omani Population with Diffuse Large B-Cell Lymphoma. 2014 , 14, e50-8	2
113	Reformatting Rituximab into Human IgG2 and IgG4 Isotypes Dramatically Improves Apoptosis Induction In Vitro. 2015 , 10, e0145633	20
112	Anti-Apoptotic Effects of Lentiviral Vector Transduction Promote Increased Rituximab Tolerance in Cancerous B-Cells. 2016 , 11, e0153069	2
111	Enhanced CDC of B cell chronic lymphocytic leukemia cells mediated by rituximab combined with a novel anti-complement factor H antibody. 2017 , 12, e0179841	5
110	---Successful Application of Whole Cell Panning for Isolation of Phage Antibody Fragments Specific to Differentiated Gastric Cancer Cells. 2019 , 9, 624-631	4

109	The H/R Fc γ IIA-131 polymorphism and survival in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP: a study in a genetically mixed population. 2011 , 66, 919-22	6
108	Simultaneous exposure to Fc γ R and Fc γ R on monocytes and macrophages enhances antitumor activity in vivo. 2017 , 8, 39356-39366	12
107	Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma. 2015 , 6, 27816-31	18
106	Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells. 2016 , 7, 12806-22	9
105	Drugs in a Curative Combination Therapy for Lymphoma Exhibit Low Cross-Resistance But Not Pharmacological Synergy.	3
104	Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy- free Era. 2019 , 26, 1002-1018	6
103	The Role of Mitochondria in Systemic Lupus Erythematosus: A Glimpse of Various Pathogenetic Mechanisms. 2020 , 27, 3346-3361	14
102	The Influence of Different Disease States on Rituximab Pharmacokinetics. 2020 , 21, 938-946	4
101	The anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia A. 2016 , 14, 255-61	14
100	Absolute monocyte and lymphocyte count prognostic score for patients with gastric cancer. 2015 , 21, 2668-76	31
99	Outcomes after liver transplantation in accordance with ABO compatibility: A systematic review and meta-analysis. 2017 , 23, 6516-6533	15
98	Immunogenicity of Rituximab, Trastuzumab, and Bevacizumab Monoclonal Antibodies in Patients with Malignant Diseases. 2018 , In Press,	2
97	A Retrospective Study on Infusion-Related Reactions to Rituximab in a Heterogeneous Pediatric Population. 2017 , 22, 369-374	5
96	A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity. 2019 , 8,	27
95	Use of anti-CD20 therapy in follicular and marginal zone lymphoma: a review of the literature. 2020 , 9,	3
94	Trial watch: intratumoral immunotherapy. 2021 , 10, 1984677	7
93	Preoperative neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are correlated with tumor node metastasis stages in patients with non-small cell lung cancer. 2021 ,	
92	The Efficacy and Safety of Different Dosages of Rituximab for Adults with Immune Thrombocytopenia: A Systematic Review and Meta-Analysis. 2021 , 2021, 9992086	3

91	Impact of Split Dosing the First Rituximab Infusion in Patients with High Lymphocyte Count. 2021 , 28, 4118-4128	0
90	Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis. 2021 , 12, 736190	3
89	Flow-FISH as a Tool for Studying Bacteria, Fungi and Viruses. 2021 , 10, 21	0
88	A topography of immunotherapies against gastrointestinal malignancies. 2021 ,	0
87	Immunotherapy in the Treatment of Autoimmune Neuromuscular Diseases. 2014 , 341-362	0
86	Novel Strategies to Improve Rituximab Efficacy in Non-Hodgkin's Lymphomas. 005-006	
85	Investigating the Molecular Specific Interactions on Cell Surface Using Atomic Force Microscopy. 417-440	
84	Rituximab capping triggers intracellular reorganization of B cells.	
83	Immunothérapie par anticorps monoclonaux : ingérierie, indications et perspectives. 2017 , 201, 1023-1035	
82	Myasthenia Gravis [A Review of Current Therapeutic Options. 2018 , 13, 86	1
81	Alkylating Agent-Induced ER Stress Overcomes Microenvironmental Resistance to Lymphoma Therapy.	
80	Genomics Role in Cancer Immunosurveillance: Impact on Immunotherapy Response. 2018 , In Press,	1
79	The Lower Peripheral Blood Lymphocyte to Monocyte Ratio Following Completion of First Line Chemotherapy Is a Risk Factor for Predicting Relapse in Patients with Diffuse Large B-Cell Lymphoma. 2019 , 10, 53-68	
78	Cancer Therapy. 2019 , 7-76	
77	Recent Advances and Therapeutic Options in Lambert-Eaton Myasthenic Syndrome. 2019 , 11, e5450	1
76	B Lymphocyte Subset Changes in Primary Membranous Nephropathy. <i>Nephro-Urology Monthly</i> , 2019 , 11,	0.4
75	Laboratory Tests Used in the Diagnosis of Immune Thrombocytopenia and General Treatment Approaches. <i>Journal of Hematology and Oncology Research</i> , 2020 , 3, 22-36	2
74	How Structures of Complement Complexes Guide Therapeutic Design. <i>Sub-Cellular Biochemistry</i> , 2021 , 96, 273-295	5.5

73	The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance. <i>Aging</i> , 2020 , 13, 181-193	5.6	1
72	Prognostic Impact of Peripheral Blood T-Cell Subsets at the Time of Diagnosis on Survival in Patients with Diffuse Large B-Cell Lymphoma. <i>Acta Haematologica</i> , 2021 , 144, 427-437	2.7	1
71	Cancer Immunoediting: Immunosurveillance, Immune Equilibrium, and Immune Escape. 2020 , 291-305		0
70	BONE MARROW TRANSPLANTATION. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2020 , 13, 273-279	0.3	2
69	Mantle cell lymphoma treatment options for elderly/unfit patients: A systematic review. <i>EJHaem</i> ,	0.9	0
68	Novel Ion Channel Targets and Drug Delivery Tools for Controlling Glioblastoma Cell Invasiveness. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
67	Therapeutic Monoclonal Antibodies in Clinical Practice against Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020 , 20, 1895-1907	2.2	1
66	Monoclonal antibodies in cancer therapy. <i>Cancer Immunity</i> , 2012 , 12, 14		182
65	Mechanisms of action of CD20 antibodies. <i>American Journal of Cancer Research</i> , 2012 , 2, 676-90	4.4	76
64	The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death. <i>American Journal of Translational Research (discontinued)</i> , 2013 , 5, 170-83	3	17
63	Anti-Lymphoma Monoclonal Antibodies: Making Better Antibodies and Making Antibodies Better. <i>Transactions of the American Clinical and Climatological Association</i> , 2015 , 126, 87-92	0.9	
62	IL-10: Expanding the Immune Oncology Horizon. <i>International Journal of Mechanical Engineering and Applications</i> , 2015 , 2,	1.3	5
61	CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas. <i>American Journal of Cancer Research</i> , 2016 , 6, 403-24	4.4	18
60	Clinical Practice Updates in the Management Of Immune Thrombocytopenia. <i>P and T</i> , 2017 , 42, 756-763	1.4	14
59	Rituximab in Pemphigus: Road Covered and Challenges Ahead. <i>Indian Dermatology Online Journal</i> , 2018 , 9, 367-372	0.9	1
58	Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018 , 9, 530-534	0.7	3
57	Getting Under the Skin: Targeting Cutaneous Autoimmune Disease. <i>Yale Journal of Biology and Medicine</i> , 2020 , 93, 197-206	2.4	0
56	Anticancer Activity of Continentalic Acid in B-Cell Lymphoma. <i>Molecules</i> , 2021 , 26,	4.8	

55	Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study.. <i>Advances in Hematology</i> , 2022 , 2022, 5581772	1.5	
54	Using immunogenetics to inform immunotherapy of lymphoid malignancies.. <i>Lancet Haematology,the</i> , 2022 , 9, e88-e89	14.6	
53	Blurry Vision as a Presentation of Waldenström's Macroglobulinemia: A Case Report With Review of Current Management.. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2022 , 10, 23247096211052187	1.2	
52	Preclinical Evaluation of Immunotoxicity. 2022 , 116-121		
51	Targeting cancer-associated glycans as a therapeutic strategy in leukemia. <i>International Journal of Transgender Health</i> , 2022 , 15, 378-433	3	0
50	Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial.. <i>Lancet Haematology,the</i> , 2022 , 9, e262-e275	14.6	1
49	Distinct mechanisms underlying therapeutic potentials of CD20 in neurological and neuromuscular disease.. <i>Pharmacology & Therapeutics</i> , 2022 , 108180	13.9	0
48	Prolonged viral positivity induced recurrent coronavirus disease 2019 (COVID-19) pneumonia in patients receiving anti-CD20 monoclonal antibody treatment: Case reports.. <i>Medicine (United States)</i> , 2021 , 100, e28470	1.8	1
47	Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 204	22.4	0
46	Rituximab Therapy for Adults with Nephrotic Syndromes: Standard Schedules or B Cell-Targeted Therapy?. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
45	Sex-Specific B Cell and Anti-Myelin Autoantibody Response After Peripheral Nerve Injury.. <i>Frontiers in Cellular Neuroscience</i> , 2022 , 16, 835800	6.1	0
44	Second and Third Generational Advances in Therapies of the Immune-Mediated Kidney Diseases in Children and Adolescents.. <i>Children</i> , 2022 , 9,	2.8	
43	table_1.PDF. 2017 ,		
42	table_2.PDF. 2017 ,		
41	Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy.. <i>Science Advances</i> , 2022 , 8, eabl9171	14.3	1
40	Rituximab in pemphigus: Road covered and challenges ahead. <i>Indian Dermatology Online Journal</i> , 2018 , 9, 367	0.9	4
39	Targeting tumor-associated macrophages for cancer immunotherapy. <i>International Review of Cell and Molecular Biology</i> , 2022 ,	6	3
38	Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper.. <i>Hematological Oncology</i> , 2022 ,	1.3	

37	Current and Future Therapies for Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2022 , 14, 2417	6.6	2
36	A review of the totality of evidence in the development of ABP 798, a rituximab biosimilar.. <i>Immunotherapy</i> , 2022 ,	3.8	0
35	Impact of glycoengineering and immunogenicity on the anti-cancer activity of a plant-made lectin-Fc fusion protein.		
34	Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression. <i>Journal of Neurology</i> ,	5.5	0
33	Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies. <i>Frontiers in Oncology</i> , 12,	5.3	0
32	IRF8 regulates efficacy of therapeutic anti-CD20 monoclonal antibodies.		0
31	Rituximab pediatric drug development: Pharmacokinetic and pharmacodynamic modeling to inform regulatory approval for rituximab treatment in patients with granulomatosis with polyangiitis or microscopic polyangiitis. <i>Clinical and Translational Science</i> ,	4.9	0
30	Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies. <i>Frontiers in Immunology</i> , 13,	8.4	0
29	Pharmacogenomics of Monoclonal Antibodies for the Treatment of Rheumatoid Arthritis. 2022 , 12, 1265		1
28	Recent Advances in SLE Treatment Including Biologic Therapies.		
27	Elevated serum level of B-cell activating factor (BAFF) after rituximab therapy in pemphigus vulgaris patients suggests a possible therapeutic efficacy of B-cell depletion therapies combined with anti-BAFF agents.		0
26	CD47-SIRPβ blocking-based immunotherapy: Current and prospective therapeutic strategies. 2022 , 12,		0
25	Study of the Stability of Sandoz Rituximab Biosimilar Rixathon® /Riximyo® When Subjected for up to 21 Days to Ambient Storage.		1
24	Impact of glycoengineering and antidrug antibodies on the anticancer activity of a plant-made lectin-Fc fusion protein.		
23	Persistent Fever and Positive PCR 90 Days Post-SARS-CoV-2 Infection in a Rituximab-Treated Patient: A Case of Late Antiviral Treatment. 2022 , 14, 1757		2
22	IRF8 regulates efficacy of therapeutic anti-CD20 monoclonal antibodies.		0
21	Immunomodulatory treatment of interstitial lung disease. 2022 , 16, 175346662211170		1
20	Immune activating and inhibiting effects of calcitriol on T cells and NK cells. 2022 , 152286		0

- 19 B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma. 13, ○
- 18 Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms. 13, ○
- 17 Case report: Successful outcome of treatment using rituximab in an adult patient with refractory minimal change disease and Ethalassemia complicating autoimmune hemolytic anemia. 9, ○
- 16 Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity. 2022, 86, 104343 ○
- 15 Editing a gateway for cell therapy across the bloodBrain barrier. ○
- 14 Systemic sclerosis. 2022, 2
- 13 A novel estrogen receptor 1: sphingomyelin phosphodiesterase acid-like 3B pathway mediates rituximab response in myositis patients. ○
- 12 Precision medicine: The use of tailored therapy in primary immunodeficiencies. 13, ○
- 11 Strategies for ABO Incompatible Liver Transplantation. 2022, ○
- 10 Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma. ○
- 9 A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndrome. 2022, 7, ○
- 8 Bendamustine and rituximab is well-tolerated and efficient in the treatment of indolent non-Hodgkin 's lymphoma and Mantle Cell Lymphoma in elderly: A single center observational study. ○
- 7 KANSER TANISI VE TEDAVISI İÇİNDE KULLANILAN MONOKLONAL ANTİKORLAR. 2023, 47, 2-2 ○
- 6 Development of Next-Generation Antibody Therapeutics Using DDS and Molecular Imaging. 2023, 1-31 ○
- 5 Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab. 2023, ○
- 4 Synthesis, spectroscopic characterization, antibacterial activity and antiproliferative profile of a new silver(I) complex of 5-fluorocytosine. 2023, 266, 110096 ○
- 3 Potential Prognostic and Predictive Role of Monocyte and Lymphocyte Counts on Presentation in Patients Diagnosed With Diffuse Large B-Cell Lymphoma. 2023, ○
- 2 Therapeutic potential of the current options in treating systemic lupus erythematosus: Challenges and prospective. 2023, 333-348 ○

1 CADD for Cancer Therapy: Current and Future Perspective. **2023**, 325-363

o